Cybin reports quarterly results and clinical progress across CYB003 and CYB004 programs

Cybin Inc. (CYBN) — Cybin delivered its quarterly financial results and business update, reiterating that its Phase 2 CYB004 study in generalized anxiety disorder had completed enrollment with topline data expected in Q1 2026, and that dosing continued in the Phase 3 APPROACH study of CYB003 in major depressive disorder.

The update underscored the company's late-stage pipeline positioning as it advanced its multinational Phase 3 PARADIGM program for adjunctive MDD treatment.

Source: investingnews.com

For the rest of that week's sector news, read our week in review.